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RESEARCH ARTICLE

YAP and TAZ maintain PROX1 expression in the developing
lymphatic and lymphovenous valves in response to VEGF-C
signaling

ABSTRACT
Lymphatic vasculature is an integral part of digestive, immune and
circulatory systems. The homeobox transcription factor PROX1 is
necessary for the development of lymphatic vessels, lymphatic valves
(LVs) and lymphovenous valves (LVVs). We and others previously
reported a feedback loop between PROX1 and vascular endothelial
growth factor-C (VEGF-C) signaling. PROX1 promotes the expression
of the VEGF-C receptor VEGFR3 in lymphatic endothelial cells
(LECs). In turn, VEGF-C signaling maintains PROX1 expression in
LECs. However, the mechanisms of PROX1/VEGF-C feedback loop
remain poorly understood. Whether VEGF-C signaling is necessary
for LV and LVV development is also unknown. Here, we report for the
first time that VEGF-C signaling is necessary for valve
morphogenesis. We have also discovered that the transcriptional
co-activators YAP and TAZ are required to maintain PROX1
expression in LVs and LVVs in response to VEGF-C signaling.
Deletion of Yap and Taz in the lymphatic vasculature of mouse
embryos did not affect the formation of LVs or LVVs, but resulted in the
degeneration of these structures. Our results have identified VEGF-C,
YAP and TAZ as a crucial molecular pathway in valve development.
KEY WORDS: PROX1, Lymphovenous valves, Valves, VEGF-C,
YAP, TAZ

INTRODUCTION

Lymphatic vasculature is an integral part of digestive, immune and
circulatory systems of vertebrates. Lymphatic vessels absorb
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interstitial fluid and return it to blood circulation (Adams and
Alitalo, 2007). In addition, specialized lymphatic vessels of the gut
known as lacteals absorb digested lipids. Lymphatic vessels regulate
immune response by transporting immune cells from tissues to
lymph nodes. Lymphatic vessels also resolve inflammation by
clearing extravasated fluids and immune cells at the site of
inflammation. Defects in lymphatic vasculature can cause
lymphedema, a disease in which tissues swell due to excessive
fluid accumulation. Currently, we lack approaches to treat
lymphedema, which has common comorbidities such as
infections, inflammation, obesity and fibrosis (Tammela and
Alitalo, 2010). Improved understanding of the mechanisms that
regulate lymphatic vascular development could provide innovative
opportunities for treating lymphedema and other lymphatic vascular
disorders.
Lymphatic vasculature is arranged in a hierarchical manner.
Blind-ended lymphatic capillaries collect interstitial fluid, immune
cells or digested lipids (simply called as lymph), and transport them
to collecting lymphatic vessels. Lymphatic valves (LVs) within the
collecting lymphatic vessels regulate the unidirectional flow of
lymph and prevent backflow. Finally, lymph travels through the
thoracic duct or the right lymphatic duct and returns to blood
circulation via two pairs of lymphovenous valves (LVVs) located
bilaterally at the intersection of jugular and subclavian veins (Geng
et al., 2016; Srinivasan and Oliver, 2011).
Lymphatic vessels, LVs and LVVs are established from
lymphatic endothelial cells (LECs) that originate predominantly
from the embryonic veins (Pichol-Thievend et al., 2018; Srinivasan
et al., 2007). Other sources could make minor contribution to the
lymphatic vasculature in a tissue-specific manner (Gancz et al.,
2019; Lioux et al., 2020; Martinez-Corral et al., 2015; Maruyama
et al., 2019; Stanczuk et al., 2015). LEC progenitors are specified in
the embryonic veins by the transcription factor PROX1, which
activates the expression of molecules such as the receptor tyrosine
kinase VEGFR3 and the glycoprotein podoplanin (Hong et al.,
2002; Petrova et al., 2002; Srinivasan et al., 2014; Wigle et al.,
2002; Wigle and Oliver, 1999). The potent lymphangiogenic
molecule VEGFC associates with VEGFR3 to promote LEC
migration from the veins to form the lymph sacs (Karkkainen et al.,
2004). A subset of LEC progenitors do not upregulate VEGFR3
expression and remain in the veins to form two pairs of LVVs
through which lymph sacs interact with the veins (Geng et al., 2016;
Srinivasan and Oliver, 2011).
Lymphatic vessels sprout from the lymph sacs to form the
primitive lymphatic plexus in various tissues. Subsequent
maturation of the lymphatic plexus results in the formation of
lymphatic capillaries and collecting lymphatic vessels (Norrmén
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et al., 2009). LVs develop within the collecting lymphatic vessels
(Bazigou et al., 2009; Norrmén et al., 2009; Petrova et al., 2004).
Maturation of lymphatic plexus and the formation of valves are
regulated by various signaling molecules such as VEGF-C,
neuropilin 2, Wnt/β-catenin, S1PR1, BMP9, ephrin B2, EPH-B4,
plexins and semaphorins (Bouvrée et al., 2012; Cha et al., 2016,
2018; Geng et al., 2020; Jurisic et al., 2012; Levet et al., 2013; Liu
et al., 2014, 2016; Makinen et al., 2005; Martin-Almedina et al.,
2016; Nurmi et al., 2015; Yuan et al., 2002). Shear stress
generated by lymph flow also plays a deterministic role in
lymphatic vascular morphogenesis (Cha et al., 2016, 2018; Choi
et al., 2019, 2017a,b; Geng et al., 2020; Liu et al., 2014; Sabine
et al., 2012; Sweet et al., 2015; Wang et al., 2016). Despite these
advances, our basic understanding of the mechanisms of
lymphatic vascular development remain incomplete. How do
the various signaling pathways coordinate with each other to
regulate lymphatic vascular development in a precise
spatiotemporal manner is not clear.
Hippo signaling controls cell proliferation, survival and
differentiation during tissue development, regeneration and
homeostasis (Zheng and Pan, 2019). The transcription co-factors
YAP (Yes-associated protein) and TAZ (transcriptional co-activator
with PDZ-binding motif ) are key downstream effectors of the
Hippo pathway. When Hippo signaling is ‘off’, non-phosphorylated
YAP and TAZ accumulate in the nucleus and interact with
transcription factors such as TEAD4, TBX5 and SMAD to induce
target genes. Importantly, YAP and TAZ function as gatekeepers of
biochemical and mechanical signaling pathways such as Wnt/βcatenin, TGFβ, GPCR, ECM stiffness and shear stress (Piccolo
et al., 2014). In the blood vasculature, YAP and TAZ promote
retinal angiogenesis and maturation of endothelial cell barrier by
regulating VEGF, BMP, Rho GTPase and biomechanical signals
(Kim et al., 2017; Neto et al., 2018; Sakabe et al., 2017; Wang et al.,
2017). Intriguingly, YAP and TAZ inhibit angiogenesis within
bones by negatively regulating HIF pathway (Sivaraj et al., 2020).
The co-repressor activity of the YAP/TAZ/TEAD4/NuRD complex
is likely responsible for the transcriptional inhibitory function of
YAP and TAZ (Kim et al., 2015).
We are starting to understand the roles of YAP and TAZ in the
mammalian lymphatic vasculature. TAZ and the ECM protein
CTGF, which is a canonical target of YAP and TAZ, are expressed
in LVs, but not in non-valvular LECs (Sabine et al., 2015).
Conditional deletion of Yap and Taz from mouse LECs disrupts the
maturation of the lymphatic vessels and results in the absence of
LVs (Cho et al., 2019). Maturation of collecting lymphatic vessels
involves the pruning of excessive branches and downregulation of
PROX1 and VEGFR3 expression (Norrmén et al., 2009; Petrova
et al., 2004). PROX1 fails to undergo downregulation in the absence
of YAP and TAZ. Furthermore, VEGF-C inhibits YAP and TAZ
activity to promote PROX1 expression in primary human LECs
(Cho et al., 2019). The downstream side of LVs experience
oscillatory shear stress (OSS), and OSS enhances the expression of
the lymphedema-associated transcription factor FOXC2 that is
necessary for LV development (Petrova et al., 2004; Sabine et al.,
2012). Importantly, FOXC2 inhibits OSS-induced YAP and TAZ
activity in primary human LECs (HLECs) (Sabine et al., 2015).
Furthermore, stiff ECM could also enhance YAP and TAZ activity
in HLECs (Frye et al., 2018). Despite these findings, whether YAP
and TAZ are required for the formation of LVs and LVVs or for their
maintenance is not known. To address this important issue, we
investigated the mechanisms of YAP and TAZ activity during LV
and LVV development in mice.
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RESULTS
YAP and TAZ are activated during valve maturation

LVV development starts at embryonic day (E) 12.0 in mice (Geng
et al., 2016; Srinivasan and Oliver, 2011). PROX1, FOXC2 and
GATA2 are upregulated in LVV-ECs, which delaminate from the
luminal side of the jugular vein. LVV-ECs rapidly reaggregate and
elongate to form mature LVVs at E12.5; after this stage, the changes
within the valves are subtle.
We performed immunohistochemistry to investigate the nuclear
localization of YAP and TAZ, and the expression of their
target molecule CTGF in LVVs starting from E12.0. YAP, TAZ
and CTGF displayed low expression in LVV-ECs until E15.5
(Fig. S1A,B). At E15.5, YAP and TAZ were detected in both the
cytoplasm and nucleus of LVV-ECs (Fig. S1C). CTGF was
observed in the ECM of LVV-ECs (Fig. S1D). By E16.5, YAP
and TAZ were predominantly nuclear in LVV-ECs (Fig. S1E), and
CTGF remains enriched in LVVs (Fig. S1F). Semi-quantitative
measurement of YAP, TAZ and CTGF expression indicates that
their expression in LVVs increases significantly between E13.5 and
E16.5 (Fig. S1G,H).
YAP and TAZ were similarly expressed in mature mesenteric
LVs (Fig. 1). Although YAP and TAZ were not expressed in newly
formed LV-ECs at E16.5 (Fig. 1A), they were detectable in
LV-ECs at E17.5 (Fig. 1B) and were strongly expressed by E18.5
(Fig. 1C,D). Angiopoietin 2 (ANGPT2), another target of YAP
and TAZ (Choi et al., 2015; He et al., 2018; Kim et al., 2017), was
also observed in LV-ECs at E18.5 (Fig. 1E). In addition, CTGF
was expressed in mature LVs as reported previously (Fig. 1F)
(Sabine et al., 2015). Together, these results suggest that the
activity of YAP and TAZ gradually increases in developing LVs
and LVVs.
YAP and TAZ are required to maintain valvular endothelial
cells

To determine the function of YAP and TAZ during
lymphangiogenesis, we used Lyve1-Cre to conditionally and
constitutively delete YAP/TAZ in the LEC progenitors from
E10.5 in mouse embryos (Pham et al., 2010; Xin et al., 2013,
2011). Lyve1-Cre;Yapflox/flox and Lyve1-Cre;Tazflox/flox mice were
born alive and were phenotypically normal. However, we did not
obtain Lyve1-Cre;Yapflox/flox;Tazflox/flox (referred to as Yap/
TazLECKO) pups. We analyzed Yap/TazLECKO mouse embryos at
various stages. Although E14.5 Yap/TazLECKO embryos did not
show any gross phenotypes, YAP and TAZ expression was
strikingly downregulated in their LECs and LVV-ECs (Fig. S2).
E15.5 Yap/TazLECKO embryos showed edema with variable
penetrance, with most embryos showing no obvious phenotype
(Fig. 2A-D).
There are two pairs of bilaterally located LVVs in mammalian
embryos (Geng et al., 2016; Srinivasan and Oliver, 2011). We
detected four LVVs in all E13.5 and most E15.5 Yap/TazLECKO
embryos (Fig. 2E-H). The number of LVVs was slightly but
significantly reduced in E15.5 Yap/TazLECKO embryos compared
with littermate controls (Fig. 2I). Strikingly, by E16.5 and E17.5,
Yap/TazLECKO embryos almost completely lacked LVVs (Fig. 2IM). Unlike control E17.5 embryos, E17.5 Yap/TazLECKO embryos
displayed only a few LVV-ECs or small holes where LVVs
normally form (Fig. 2M, white arrowhead and higher
magnification inset). Venous valves that develop close to LVVs
are a part of the blood vasculature, although they share the same
molecular profile as LVVs (Bazigou et al., 2011; Geng et al., 2016;
Munger et al., 2016, 2013; Srinivasan and Oliver, 2011).
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Fig. 1. YAP and TAZ activity is
upregulated in LVs undergoing
maturation. (A-C″) Mesenteric lymphatic
vessels from E16.5 (A-A″), E17.5 (B-B″)
and E18.5 (C-C″) embryos were analyzed
for the expression of TAZ. A gradual
increase in the expression of TAZ was
observed in the LVs from E16.5 to E18.5
(arrows). (D-F) Immunohistochemical
analysis of E18.5 mesenteric vessels
revealed strong expression of YAP and
TAZ (D), and their targets ANGPT2 (E) and
CTGF (F) in the LVs (arrows). n=3 embryos
per stage per antibody. Scale bars: 200 µm
in A-C″; 100 µm in D-F.

YAP and TAZ positively regulate PROX1 expression in
primary human LECs

The small molecule verteporfin (VP) disrupts the interaction between
YAP, TAZ and TEAD, thereby inhibiting the transcriptional activity
of YAP and TAZ. Primary human LECs (HLECs) treated with VP for
2 h showed reduced expression of the canonical YAP and TAZ target
genes CTGF (CCN2), CYR61 (CCN1) and ANKRD1, as expected
(Fig. 4A). To comprehensively identify the transcriptional targets of
the TEAD/YAP/TAZ complex, we treated HLECs with 20 µM VP
for 2 h, extracted RNA and performed RNA-seq analysis. Based on
the Log2(fold change) >1 that we set for differentially expressed
genes, we determined that 794 genes were upregulated and 2161
genes were downregulated by VP [Fig. 4B and see data in the Dryad
Digital Repository (Cha et al., 2020) and Table S1]. Gene ontology
(GO) analysis showed that VP altered the expression of genes that
regulate vascular development (Fig. 4C). Genes that regulate
lymphangiogenesis, such as PROX1, FLT4, ANGPT2 and DLL4
were also dramatically downregulated in VP-treated HLECs
(Fig. 4D).
PROX1 is the master regulator of lymphatic vascular
development and is required for the formation and maintenance of
LVs and LVVs (Geng et al., 2016; Johnson et al., 2008; Srinivasan
and Oliver, 2011). We verified that VP treatment of HLECs reduces
PROX1 expression at the RNA and protein levels (Fig. 5A).
Importantly, siRNA-mediated knockdown of YAP and TAZ also
reduced PROX1 levels in HLECs (Fig. 5A,B).
The ENCODE database predicted a TEAD4-binding site in the
regulatory elements of PROX1, close to the GATA2-binding site
that was reported previously (Fig. 5C) (ENCODE Project
Consortium, 2012; Kazenwadel et al., 2015). Using a targeted
3
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Consistent with Lyve1-Cre activity in embryonic veins, E17.5 Yap/
TazLECKO embryos also lacked venous valves (Fig. 2K,M, yellow
arrowheads).
E16.5 Yap/TazLECKO embryos lacked observable defects in the
lymphatic vessels of the dorsal skin, and LV-forming endothelial
cells were observed within their lymphatic vessels of the mutants
(Fig. 3A,B, arrows). However, by E18.5, Yap/TazLECKO embryos
had defective lymphatic vessels that were more dilated, had fewer
branch points and did not migrate sufficiently from the lateral edges
(Fig. 3E-G). In addition, unlike control embryos (Fig. 3H, arrows),
E18.5 Yap/TazLECKO embryos no longer had any LVs (Fig. 3G,I).
The mesenteric lymphatic vessels of E18.5 Yap/TazLECKO
embryos were immature, as suggested by strong expression of
LYVE1, VEGFR3 and PROX1 (Fig. S3). LVs were missing from
these immature collecting vessels (Fig. S3C-G). However, the guts
of Yap/TazLECKO embryos were much smaller in size when
compared with controls (Fig. S3E,F). This is likely due to the
blood vascular defects caused by Lyve1-Cre expression in the blood
vessels of the gut, as reported previously (Dellinger et al., 2013;
Geng et al., 2020). Consequently, we are unable to conclude
whether the defects in the mesenteric lymphatic vessels of Yap/
TazLECKO embryos are due to YAP and TAZ activity in LECs or to
blood vascular endothelial cells. Nevertheless, Lyve1-Cre is specific
to dermal lymphatic vasculature (Dellinger et al., 2013; Geng et al.,
2020). Hence, based on our findings we conclude that YAP and
TAZ are not required for the differentiation of valvular endothelial
cells (LVVs and LVs). This conclusion coincides with the lack of
YAP and TAZ expression and activity in the newly differentiated
valvular endothelial cells. However, LVVs and LVs degenerate in
the absence of YAP and TAZ.
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approach, we verified that a TEAD4-binding site (Fig. 5D) is indeed
present in the upstream regulatory elements of PROX1, and is
conserved among several mammals (Fig. 5E). Furthermore, ChIPPCR revealed that YAP binds to this site in HLECs (Fig. 5F).
Together, these data suggest that YAP/TAZ cooperates with
TEAD4 to directly activate PROX1 expression in HLECs.
However, the functional significance of this binding site is
currently unknown, and it is likely that YAP and TAZ associate
with multiple sites in the distal regulatory elements of genes, as
described previously (Galli et al., 2015; Stein et al., 2015).
Activation of the Hippo signaling pathway leads to MST1/2mediated phosphorylation and activation of LATS1/2, which in turn
phosphorylate and inactivate YAP/TAZ. Therefore, to enhance
YAP/TAZ activity in HLECs, we treated cells with XMU-MP-1, a
chemical inhibitor of MST1 and MST2, or knocked down LATS1

and LATS2 (siLATS1/2). Both treatments resulted in the
upregulation of the YAP and TAZ target genes CTGF and
CYR61, as anticipated (Fig. S4A,B). In contrast, PROX1
expression was downregulated by siLATS1/2 and XMU-MP-1
treatments (Fig. S4A,B), consistent with recent findings of Cho
et al. (Cho et al., 2019). Thus, PROX1 expression in HLECs is
delicately dependent on the activity of YAP and TAZ.
To test whether YAP and TAZ regulate Prox1 expression in vivo,
we bred Prox1-tdTomato transgenic reporter mice into the Yap/
TazLECKO background. In the Prox1-tdTomato transgenic mice the
expression of tdTomato is driven by ∼100 kb regulatory elements of
Prox1 (Gong et al., 2003). Thus, the transcriptional regulation of
Prox1 could be visualized using Prox1-tdTomato mice. Compared
with Prox1-tdTomato littermate controls, Prox1-tdTomato; Yap/
TazLECKO embryos showed dramatically reduced expression of
4
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Fig. 2. YAP and TAZ are required for the maintenance of LVVs. (A) Control E15.5 mouse embryo. (B-D) A subset of E15.5 Lyve1-Cre;Yapf/f;Tazf/f embryos
developed edema (B, arrowheads) or blood-filled lymphatic vessels (D, arrowheads). The rest of the embryos had mild edema (C, arrowhead) or no
obvious defects. The number of embryos analyzed in total and the number of embryos that had the represented phenotype are indicated in each panel.
(E-H) Immunohistochemistry or scanning electron microscopy was used to analyze the LVVs of E13.5 (E,F) and E15.5 (G,H) embryos. LVVs (arrows) were
observed in both control (E,G) and Lyve1-Cre;Yapf/f;Tazf/f (F,H) embryos. (I) Every embryo has four LVVs. We analyzed n=4 embryos/genotype/stage and
calculated the average number of LVVs per embryo. (J-M) E16.5 (J,K) and E17.5 (L,M) embryos were analyzed by immunohistochemistry or scanning electron
microscopy. LVVs (white arrows) and venous valves (yellow arrows) were seen in control embryos (J,L). In contrast, only few PROX1+ valvular endothelial cells
were seen in E16.5 Lyve1-Cre;Yapf/f;Tazf/f embryos (K, arrowheads). Scanning electron microscopy revealed abnormal holes in place of LVVs (M, white
arrowhead) and a few venous valve-forming endothelial cells (M, yellow arrowhead). *P<0.05, ****P<0.0001. Data are mean±s.e.m. Scale bars: 100 µm in
E-H,J,K; 200 µm in L,M.

RESEARCH ARTICLE

Development (2020) 147, dev195453. doi:10.1242/dev.195453

Fig. 3. YAP and TAZ are required for the maintenance of LVs. The lymphatic vessels in the dorsal skin of E16.5 and E18.5 control and Lyve1-Cre;Yapf/f;Tazf/f
embryos were analyzed by whole-mount immunohistochemistry. (A,B) LVs were observed in the collecting lymphatic vessels of E16.5 control and Lyve1-Cre;
Yapf/f;Tazf/f embryos (arrows). (C,D) The migrating front of E16.5 control (C) and Lyve1-Cre;Yapf/f;Tazf/f (D) embryos appeared comparable. (E-G) At E18.5, the
lymphatic vessels from the left and right sides have merged to form a network in control embryos (E). In contrast, huge gaps were observed in between the
migrating fronts of E18.5 Lyve1-Cre;Yapf/f;Tazf/f embryos (F, magenta lines). The lymphatic vessels of mutant embryos were also dilated. The distance between
the migrating fronts and the diameter of vessels are quantified in G. (H,I) LVs were observed in the collecting lymphatic vessels of E18.5 control embryos (H, yellow
arrows). In contrast, the dilated lymphatic vessels of E18.5 Lyve1-Cre;Yapf/f;Tazf/f embryos lacked LVs (I). The various parameters of lymphatic vascular
patterning were quantified and are plotted in G. n=4 embryos per each genotype. ****P<0.0001. Data are mean±s.e.m. Scale bars: 200 µm in A-D; 500 µm in E,F;
200 µm in H,I.

that CTGF is expressed exclusively in the valves (Fig. 1, Fig. S1 and
Sabine et al., 2015). In summary, we infer that Yap and Taz are thus
required to maintain valvular endothelial cell identity at least in part
by promoting Prox1 expression.
Yap and Taz genetically interact with Prox1 in lymphatic
vasculature development

To further investigate the relationship between PROX1, YAP and
TAZ, we deleted Yap and Taz in PROX1-expressing cells,
including LECs, using Prox1+/Cre. In these mice, one functional
allele of Prox1 is replaced by Cre recombinase, resulting in
impaired LVV development (Srinivasan et al., 2010; Srinivasan
and Oliver, 2011). E14.5 Prox1+/Cre;Yap+/f;Taz+/f embryos
lacked LVVs, as expected, as did E14.5 Prox1+/Cre;Yap/
TazLECKO embryos (Fig. 7A-C). The glycoprotein endomucin
is expressed in venous endothelial cells, but not in LECs
(D’Amico et al., 2009). Both E14.5 wild-type and Prox1+/Cre;
Yap+/f;Taz+/f embryos displayed endomucin expression in
venous endothelial cells but not in LECs lining the lymph sacs
5
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PROX1 and tdTomato in LVV-ECs (Fig. 6A,B, arrows; Fig. 6C)
and in LECs of lymph sacs (Fig. 6A,B, arrowheads; Fig. 6C) at
E15.5.
As mentioned previously, PROX1high; tdTomatohigh LVs that
were observed in the dermal lymphatic vessels of E18.5 Prox1-tdTomato embryos (Fig. 6D, arrows) were absent in Prox1-td-Tomato;
Yap/TazLECKO littermates (Fig. 6E). Moreover, Prox1 and other
YAP/TAZ target genes showed reduced expression in LECs isolated
from Yap/TazLECKO embryos compared with controls (Fig. 6F). We
wanted to determine whether the observed downregulation of Prox1
in Yap/TazLECKO embryos is due to the absence of LVs or also due to
reduced Prox1 expression in LECs. Therefore, we measured the
intensities of PROX1 and tdTomato signals in a semi-quantitative
manner from E18.5 Prox1-td-Tomato and Prox1-td-Tomato; Yap/
TazLECKO embryos (Fig. 6G). Expression of tdTomato, but not
PROX1, was modestly downregulated in the LECs of Prox1-tdTomato; Yap/TazLECKO embryos. These results suggest that YAP
and TAZ are necessary to maintain PROX1 expression primarily in
valvular endothelial cells. This conclusion is supported by the fact

RESEARCH ARTICLE

Development (2020) 147, dev195453. doi:10.1242/dev.195453

Fig. 4. YAP and TAZ regulate the expression of genes that are involved in lymphatic vascular development. (A) Treatment of HLECs with VP resulted in the
downregulation of YAP and TAZ target genes. (B) RNA-seq data were analyzed using a volcano plot to reveal the differentially expressed (DE) genes in VPtreated HLECs. (C) Gene ontology (GO) analysis revealed that several pathways that are crucial for vascular development were affected by VP treatment. (D)
Heat map shows that the expression of several genes that are crucial for vascular development were affected by VP treatment. n=4 independent experiments per
group.

embryos developed cystic structures in their lymphatic vessels
(Fig. S5C), whereas wild-type and Prox1+/Cre;YapLECHet;TazLECHet
embryos did not. We propose that Prox1+/Cre;TazLECHet;YapLECKO
embryos express relatively low levels of PROX1 compared with
Prox1+/Cre;TazLECHet;YapLECHet embryos, which exacerbates defects
in lymphatic vessel morphogenesis. Overall, our data reveal that
genetic reduction of Prox1 together with Yap and Taz results in the
partial loss of LEC identity and improper morphogenesis of
lymphatic vessels.
VEGF-C signaling promotes PROX1 expression in HLECs
through YAP and TAZ

PROX1 expression is positively regulated by VEGF-C signaling in
HLECs (Koltowska et al., 2015; Srinivasan et al., 2014). We
hypothesized that VEGF-C/VEGFR3 signaling activates PROX1
expression in LECs through YAP/TAZ. We treated high confluent
(∼100%) or low confluent (∼50%) HLECs with 100 ng/ml VEGFC and investigated the phosphorylation of YAP. We determined that
pYAP is strikingly reduced by VEGF-C specifically in low
confluent cells (Fig. S6). Thus VEGF-C regulates the
phosphorylation of YAP in a cell density-dependent manner.
6
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(Fig. 7A,B). In contrast, E14.5 Prox1+/Cre;Yap/TazLECKO embryos
expressed endomucin in the lymph sacs (Fig. 7C,C″,D). This
observation suggests that a subset of LECs in Prox1+/Cre;Yap/
TazLECKO embryos have abnormally acquired a partial blood vascular
endothelial cell identity. This phenotype is also observed in embryos
that completely lose Prox1 after the specification of LECs (Johnson
et al., 2008). Hence, we studied the expression of PROX1 by
immunohistochemistry and found that it was indeed downregulated in
the LECs of Prox1+/Cre;Yap/TazLECKO embryos compared with their
littermates (Fig. 7E-H).
We were unable to obtain Prox1+/Cre;Yap/TazLECKO embryos
beyond E14.5, likely due to the expression of Cre in hepatocytes,
which rely on YAP and TAZ for their growth (Camargo et al., 2007;
Dong et al., 2007). Therefore, we analyzed E17.5 Prox1+/Cre;
TazLECHet;YapLECKO and Prox1+/Cre;YapLECHet;TazLECHet embryos.
At E17.5, the lymphatic vessels of wild-type embryos had crossed
the dorsal midline and LVs were observed at the lateral edges of
the skin (Fig. S5A and data not shown). In contrast, the
lymphatic vessels were dilated and did not reach the midline in
Prox1+/Cre;TazLECHet;YapLECKO and Prox1+/Cre;YapLECHet;TazLECHet
embryos (Fig. S5B,C). Intriguingly, Prox1+/Cre;TazLECHet;YapLECKO
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Fig. 5. YAP and TAZ regulate the expression of PROX1 in HLECs potentially through a conserved TEAD4-binding site. (A) Inhibition of YAP and TAZ
activity in HLECs by VP or siRNAs results in the downregulation of PROX1 at RNA and protein levels. IB, immunoblot. (B) Immunocytochemistry revealed
that the expression of PROX1 is downregulated in HLECs by siRNAs targeting YAP and TAZ. (C) The PROX1 regulatory element was analyzed using the
ENCODE database. A TEAD4-binding site was observed ∼10 kb upstream of the transcriptional start site of human PROX1 regulatory elements. (D) The DNA
recognition motif of TEAD4. (E) PROX1 regulatory elements from the indicated mammals were aligned using Clustal Omega. A highly conserved GATA2-binding
site reported by Kazenwadel et al. (2015) is within the red box. TEAD4-binding sites that are conserved either between rat/mouse or between dog/human/
chimpanzee are underlined. Asterisks indicate conserved nucleotides. (F) ChIP followed by PCR using primers that flank the TEAD4-binding site
revealed that YAP and TAZ directly associate with this regulatory element. n=3 western blot, qRT-PCR and ChIP assays. **P<0.01, ***P<0.001.
Data are mean±s.e.m. Scale bar: 100 µm in E.

To test whether VEGF-C regulates Hippo signaling, we treated
50% confluent HLECs with VEGF-C and isolated RNA and
protein. We found that the expression of YAP and TAZ target genes
was significantly upregulated in VEGF-C-treated HLECs relative to
controls (Fig. 8A). Additionally, VEGF-C treatment inhibited the

phosphorylation of YAP, as mentioned above (Fig. 8A,B). In
contrast, VEGF-A did not increase the expression of YAP and TAZ
target genes or reduce the level of pYAP (Fig. 8A,B). Thus, YAP
and TAZ activity is enhanced by VEGF-C, but not by VEGF-A in
HLECs.
7
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VEGF-C increased the levels of YAP in the nucleus of HLECs
(Fig. 8C). Moreover, VP treatment and siRNA-mediated
knockdown of YAP and TAZ inhibited the VEGF-C dependent
upregulation of PROX1 in HLECs (Fig. 8D). We used 293T cells as
a heterologous system to further verify whether VEGF-C and
VEGFR3 signaling could enhance YAP and TAZ activity. We
infected 293T cells with lentiviruses expressing VEGFR3.
Following antibiotic selection, we treated stably infected cells
with VEGF-C for 0.5 or 2 h. Western blotting and qRT-PCR
confirmed that VEGF-C could indeed downregulate pYAP and
upregulate the expression of YAP/TAZ target genes (Fig. 8E).
Together, these data suggest that VEGF-C activates YAP and TAZ

activity in HLECs and VEGFR3-expressing 293T cells.
Furthermore, VEGF-C promotes PROX1 expression in HLECs
through YAP and TAZ.
Next, we investigated whether the Hippo pathway regulates
VEGF-C induced behaviors in HLECs. To examine HLEC
migration, we performed an in vitro wound-healing assay. VEGFC treatment promoted the migration of HLECs, as anticipated (Fig.
S7A,B,E). Importantly, VP treatment significantly inhibited VEGFC-induced HLEC migration (Fig. S7C-E). Additionally, siRNAmediated depletion of YAP and TAZ significantly reduced VEGFC-induced HLEC proliferation (Fig. S7F-J). Thus, YAP and TAZ
are necessary for the proper response of HLECs to VEGF-C.
8
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Fig. 6. YAP and TAZ regulate PROX1 expression in
valvular endothelial cells. (A-C) E15.5 Prox1-tdTomato
(A-A″) and Prox1-tdTomato; Lyve1-Cre;Yapf/f;Tazf/f
(B-B″) embryos were frontally sectioned and the
expression of PROX1 and tdTomato (TOM) were
analyzed by immunohistochemistry. The fluorescent
intensity of tdTomato is semi-quantitatively measured in
C. The expression of PROX1 and tdTomato were
downregulated in LECs (arrowheads) and LVV-ECs
(arrows) of embryos lacking YAP and TAZ. (D-E″)
PROX1high;tdTomatohigh LVs that were observed in E18.5
Prox1-tdTomato embryos (D-D″, arrows) were absent
from Prox1-tdTomato; Lyve1-Cre;Yapf/f;Tazf/f littermates
(E-E″). (F) LECs were sorted from the skin of E18.5
control or Lyve1-Cre;Yapf/f;Tazf/f littermates and qRTPCR was performed using the extracted RNA. The
expression of Yap, Taz, Prox1, and other YAP and TAZ
target genes were downregulated in the LECs from mutant
embryos. (G) The fluorescent intensities of PROX1 and
tdTomato expression from samples shown in D,E were
measured in a semi-quantitative manner. tdTomato
expression was modestly downregulated in the lymphatic
vessels of mutants. However, PROX1 expression
appeared to be unchanged. In A-C, n=4 embryos and 8
pairs of LVVs for each genotype. In D-G, n=4 embryos per
genotype. **P<0.01, ***P<0.001, ****P<0.0001. Data are
mean±s.e.m. Scale bars: 100 µm in A-B″,D-E″.
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VEGF-C promotes YAP and TAZ activity in vivo

Our in vitro studies indicate that VEGF-C signaling enhances YAP
and TAZ activity. Our in vivo results have revealed that YAP and
TAZ are required for lymphatic vessel, LVV, LV and venous valve
morphogenesis. VEGF-C signaling is necessary for the
development and maintenance of lymphatic vessels (Karkkainen
et al., 2004, 2001; Nurmi et al., 2015). In addition, VEGFR3 is
strongly expressed in LVs (Bazigou et al., 2009; Norrmén et al.,
2009). Time-specific global deletion of Vegfc at E14.5 prevented
the maturation of collecting lymphatic vessels and the development
of LVs within the collecting lymphatic vessels (Nurmi et al., 2015).
However, as the lymphatic vessels of these mice were thinner and
immature, whether VEGF-C directly or indirectly regulates LV
development remains unknown. VEGFR3 is also modestly
expressed in LVVs and venous valves (Bazigou et al., 2011;
Geng et al., 2016). Saphenous venous reflux is observed in
individuals with Milroy’s disease carrying mutations in VEGFR3
(Mellor et al., 2010). Yet, it is unclear whether LVV and venous
valve development requires VEGF-C and VEGFR3 signaling.
To investigate the relationship between VEGF-C and VEGF3
signaling and Hippo signaling in vivo, we analyzed three mouse
models in which VEGF-C signaling was inhibited. We generated

Vegfc+/CreERT2 mice in which we replaced the open reading frame of
Vegfc with cDNA coding for CreERT2. Vegfc +/CreERT2 mice
recapitulated the phenotypes of Vegfc +/− mice, including severe
lymphatic vascular hypoplasia in the skin (Fig. S8). In addition,
Vegfc +/CreERT2 mice developed chylous ascites at birth, swollen
paws and tail and lymphatic vascular hypoplasia of the heart
and diaphragm as reported previously in Vegfc +/− mice (Karkkainen
et al., 2004). Vegfc+/CreERT2 mice will henceforth be referred to as
Vegfc+/− mice in this study.
LVVs appeared normal in E15.5 Vegfc+/− embryos (Fig. S9A,B,
arrows). Venous valves were also present in E17.5 Vegfc+/−
embryos (Fig. S10A,B, red arrowheads). Similarly, LVVs and
venous valves were observed in Vegfr3+/chy embryos, which express
a dominant-negative allele of VEGFR3 and phenocopy Vegfc+/−
mice (Fig. S9C,D, pseudo-colored in magenta and yellow,
respectively) (Karkkainen et al., 2001). These results suggest that,
despite severe lymphatic vascular defects, LVV and venous valve
development are not affected in Vegfc+/− and Vegfr3+/chy embryos.
We analyzed LVVs and venous valves in E17.5 Vegfr3+/EGFP;
Vegfc+/− embryos in which VEGF-C and VEGFR3 signaling is
expected to be more than in Vegfc−/−, but less than in Vegfc+/−
embryos. LVVs and venous valves were observed in wild-type and
9
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Fig. 7. Deletion of YAP and TAZ aggravates the lymphatic vascular defects associated with Prox1 heterozygosity by further downregulating the
expression of PROX1. E14.5 wild-type (A-A″,E-E″), Prox1+/Cre;Yap+/f;Taz+/f (B-B″,F-F″) and Prox1+/Cre;Yap/TazLECKO (C-C″,G-G″) littermates were
sectioned and the expressions of endomucin and PROX1 were analyzed. (A-D) In wild-type and Prox1+/Cre;Yap+/f;Taz+/f embryos (A-B″), endomucin was
expressed in the venous endothelial cells (A′,B′), but not in the LECs lining the lymph sacs (A″,B″). In contrast, patchy expression of endomucin was observed
within the LECs of Prox1+/Cre;Yap/TazLECKO embryos (C″). The fluorescent intensity of endomucin expression in LECs was measured and is plotted in D.
(E-H) PROX1 was strongly expressed in the LVV-ECs of wild-type embryos (E′). LVVs were absent in Prox1+/Cre;Yap+/f;Taz+/f and Prox1+/Cre;Yap/TazLECKO
embryos (F′,G′). Additionally, PROX1 expression was downregulated in the LECs of Prox1+/Cre;Yap/TazLECKO embryos (G″) compared with wild-type and
Prox1+/Cre;Yap+/f;Taz+/f littermates (E″,F″). The fluorescent intensity of PROX1 expression was measured and is plotted in H. n=4 for each genotype.
**P<0.01, ***P<0.001, ****P<0.0001. Data are mean±s.e.m. Scale bars: 200 µm in A,B,C,E,F,G; 100 µm in A′,A″,B′,B″,C′,C″,E′,E″,F′,F″,G′,G″.
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Vegfr3+/EGFP embryos, as anticipated (Fig. 9A,B, white arrows and
white arrowheads, respectively). Lymph sacs were observed, but
LVVs were absent in E17.5 Vegfr3+/EGFP;Vegfc+/− embryos
(Fig. 9C, red arrows). In contrast, venous valves of Vegfr3+/EGFP;
Vegfc+/− embryos appeared indistinguishable from control
littermates (Fig. 9C, white arrowheads). These results suggest that
LVVs are more reliant on VEGF-C signaling for their development
compared with venous valves.
We also analyzed E17.5 Vegfr3chy/chy embryos in which VEGFC/VEGFR3 signaling is completely abolished (Karkkainen et al.,
2001; Zhang et al., 2010). Lymph sacs and LVVs were absent from
these embryos (Fig. 9D, asterisk and red arrow, respectively).

Importantly, very few PROX1+ cells were observed on the walls of
veins where venous valves normally form (Fig. 9D, yellow
arrowheads). It is possible that the lack of lymph sacs resulted in
the absence of LVVs and venous valves. To test this possibility, we
generated a new double-transgenic mouse model to abolish
VEGF-C and VEGFR3 signaling in a time-specific manner after
the development of lymph sacs. In these mice, 3rd generation
reverse tetracycline-regulated transactivator (rtTA3) is expressed
from the Rosa26 locus and is regulated by CAGG regulatory
elements (CMV enhancer with chicken β-actin promoter). In
addition, a miRNA-based shRNA targeting Vegfr3 is expressed
from tetracycline response element (TetO) that is knocked into the
10
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Fig. 8. VEGF-C enhances YAP and TAZ
activity in HLECs and in 293T cells
expressing VEGFR3. (A,B) HLECs were
treated with 100 ng/ml of VEGF-A or
VEGF-C for 2 or 4 h following which RNA
or protein was extracted to quantify the
transcriptional activity of YAP and TAZ.
Intensities of western bands were
measured and plotted in B. The
expression of YAP and TAZ target genes
CTGF and CYR61 was upregulated by
VEGF-C, but not by VEGF-A.
Additionally, phosphorylation of YAP was
specifically reduced by VEGF-C. (C)
VEGF-C promoted the nuclear
localization of YAP in HLECs. N, nuclear
localization; C, cytoplasmic localization.
(D) Treatment of HLECs with VEGF-C for
24 h enhanced the expression of PROX1
at both RNA (graph on the left) and
protein (western blot on the right) levels.
Inhibition of YAP and TAZ activity either
by VP or by siRNA abolished the
enhancement of PROX1 expression by
VEGF-C. (E) 293T cells were stably
infected with GFP or VEGFR3overexpressing (OE) lentiviral particles
and treated with VEGF-C for the
indicated time points. Phosphorylation of
YAP was reduced and the expression of
YAP and TAZ target genes was
increased by VEGF-C in VEGFR3 OE
cells. n=5 for VEGF-C treatment in A; n=4
for western blotting in E; n=3 per each of
the other experiments. *P<0.05,
**P<0.01, ***P<0.001. Western blots
were quantified and results presented as
mean±s.d. Other data are presented as
mean±s.e.m. Scale bar: 100 µm.
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constitutively active Col1a1 locus (Premsrirut et al., 2011).
Doxycycline (Dox), when administered in food, will activate
rtTA3. Transcriptionally active rtTA3 will bind TetO to activate
the expression of shRNA that will knock down Vegfr3. We
exposed these ShVegfr3;rtTA3 embryos to Dox from E12.5, after
the formation of lymph sacs, and analyzed them at E17.5. The
dorsal skin of E17.5 ShVegfr3;rtTA3 embryos was devoid of
lymphatic vessels, which is consistent with the phenotypes of
Vegfc+/− and Vegfr3+/chy embryos (Fig. 9E,F) (Karkkainen et al.,
2004, 2001). Lymph sacs were observed in E17.5 ShVegfr3;rtTA3
embryos (Fig. 9G,H). However, they lacked LVVs (Fig. 9H, red
arrow) and their venous valves were severely reduced in size (Fig. 9H,
yellow arrowhead). The results from Vegfr3chy/chy and ShVegfr3;

rtTA3 embryos indicates that VEGF-C signaling is essential for the
development of LVVs and venous valves.
Having determined that VEGF-C signaling is necessary for valve
development, we tested whether YAP/TAZ activity is
downregulated in Vegfc+/− embryos. The LV-ECs of E18.5 wildtype embryos had aggregated with each other, giving the LVs a
compact and mature appearance (Fig. 10A, arrow). The YAP/TAZ
target protein CTGF was expressed in the LVs of wild-type embryos
(Fig. 10A, arrow). In contrast, there were fewer LVs in E18.5
Vegfc+/− embryos (Fig. 10B; data not shown). The LVs that were
observed in E18.5 Vegfc+/− embryos were immature and CTGF was
dramatically downregulated in the developing LVs of Vegfc+/−
littermates (Fig. 10C, arrow). LVs further matured in 2-day-old (P2)
11
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Fig. 9. VEGF-C regulates the formation of LVVs. (A-D) LVVs (arrows)
and venous valves (arrowheads) were found in E17.5 wild-type (A) and
Vegfr3+/EGFP (B) embryos. (C) Vegfr3+/EGFP;Vegfc+/− embryos had the
venous valves (arrowheads). However, LVVs were absent in the areas
where they would have normally formed (red arrows). (D) E17.5 Vegfr3chy/chy
embryos lacked lymph sacs (asterisk) and LVVs (red arrow). In addition, only
a few venous valve-forming cells were observed (yellow arrowheads). (E,F)
Lymphatic vessels were absent from the dorsal skin of E17.5 shVegfr3;rtTA3
embryos that were treated with doxycycline from E12.5 (F). (G,H) Lymph
sacs (LS), LVVs (G, arrows) and venous valves (G, arrowheads) that were
seen in E17.5 wild-type embryos were absent from shVegfr3;rtTA3
littermates. Red arrow in H indicates the location at which LVVs would have
normally formed. Yellow arrowhead in H indicates the few remaining venous
valve-forming endothelial cells. LS, lymph sac; IJV, internal jugular vein;
EJV, external jugular vein; SCV, subclavian vein; SVC, superior vena cava.
In A-D,G,H, n=3 embryos per genotype and 2 LVV/venous valve complexes
per embryo; in E,F, n=5 dorsal skins from 5 embryos per genotype. Scale
bars: 200 µm in A-D,G,H; 1000 µm in E,F.
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wild-type pups, and expressed TAZ and the YAP and TAZ target
protein ANGPT2 (Fig. 10D,E, arrows). In contrast, the LVs of
P2 Vegfc+/− littermates remained immature and did not express
ANGPT2 (Fig. 10F, arrow). TAZ expression was also
downregulated in the LVs of P2 Vegfc+/− pups (Fig. 10G, arrow).
YAP and TAZ expression was also downregulated in the mesenteric
LVs of P2 Vegfr3+/chy pups and E18.5 shVegfr3;rtTA3 embryos that
were exposed to Dox for 2 days (Fig. S11). We sorted LECs from
the mesentery of P2 wild-type and Vegfc+/− pups, extracted RNA
and performed qRT-PCR to estimate the expression of YAP and
TAZ target genes. The expression of Prox1 and other YAP and TAZ
target genes, Ctgf and Cyr61, was downregulated in the LECs of
Vegfc+/− pups (Fig. 10H). These results suggest that VEGF-C
enhances YAP and TAZ activity in LVs.
In summary, VEGF-C and VEGFR3 signaling regulates LV,
LVV and venous valve development. YAP and TAZ are essential
mediators of VEGF-C signaling during valve development. VEGFC signaling enhances the transcriptional activity of YAP and TAZ to
promote the expression of genes such as PROX1, CTGF and
ANGPT2 that are potently expressed in valves. Consequently, in the
absence of YAP and TAZ, the development of lymphatic vessels,
LV, LVV and venous valves is defective.
DISCUSSION

Our work has identified several previously unknown mechanisms
that operate during lymphatic vascular development. We and others
have previously reported a feedback loop between PROX1 and the
VEGF-C/VEGFR3 signaling pathway in LECs (Koltowska et al.,
2015; Srinivasan et al., 2014). PROX1 directly activates the
expression of VEGFR3. In turn, VEGF-C and VEGFR3 signaling

maintains the expression of PROX1. The mechanisms by which
VEGF-C and VEGFR3 signaling regulates PROX1 expression are
not fully understood. Here, we have identified YAP and TAZ as
critical mediators of the PROX1 expression in response to VEGF-C
signaling. VEGF-C is unable to enhance PROX1 expression in
HLECs in the absence of YAP and TAZ. This finding establishes
YAP and TAZ as crucial components of the PROX1 and VEGFR3
feedback loop.
PROX1, FOXC2, GATA2 and VEGFR3 are expressed at much
higher levels in valvular endothelial cells compared with the rest of
the lymphatic vasculature (Bazigou et al., 2009; Geng et al., 2016;
Kazenwadel et al., 2015; Norrmén et al., 2009). Previous reports,
including our own, have shown that PROX1, FOXC2 and GATA2
are necessary for the development of LVs and LVVs (Geng et al.,
2016; Kazenwadel et al., 2015; Mahamud et al., 2019; Norrmén
et al., 2009; Petrova et al., 2004). However, whether VEGFR3 is
necessary for the development of valves has not been demonstrated,
although superficial venous valve reflex is observed in individuals
with Milroy’s disease, which is characterized by heterozygous
inactivating mutations in VEGFR3 (Mellor et al., 2010). In this work
we have shown that VEGF-C and VEGFR3 signaling is indeed
required for the proper development of LVs, LVVs and venous
valves. Furthermore, we show that VEGF-C and VEGFR3 signaling
activates YAP and TAZ, which in turn maintains the expression of
PROX1 in valvular endothelial cells. These data suggest that the
PROX1 and VEGFR3 feedback loop is operational in developing
valves. Intriguingly, deletion of Yap and Taz did not affect the
differentiation of valvular endothelial cells. Instead, between E16.5
and E18.5, PROX1 expression was downregulated and LVs and
LVVs degenerated in the absence of YAP and TAZ. Thus, YAP and
12
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Fig. 10. Expression of YAP and TAZ
targets is downregulated in the LVs
of Vegfc+/− embryos. (A-G″) LVs in the
mesenteric lymphatic vessels of E18.5
(A-C″) or P2 (D-G″) wild-type and
Vegfc+/− embryos were analyzed for
the expression of PROX1 and other
YAP/TAZ target genes. PROX1
(A,A″,D,D″,F,F″), CTGF (A,A′),
ANGPT2 (D,D′) and TAZ (F,F′) were
strongly expressed in the LVs of wildtype embryos and pups. In contrast, the
LVs of Vegfc+/− mice appeared
immature, as interpreted from the lack of
PROX1+ clusters at sites where LVs
would have normally formed (B, arrow),
the dispersed characteristic of PROX1+
cells in the LVs that are forming (C,
arrow, and C″), the absence of the
dome-shaped structure (F, arrow) and
reduced expressions of CTGF (B′,C′),
ANGPT2 (F′) and TAZ (G′). (H) LECs
were sorted from the mesentery of P2
wild-type and Vegfc+/− pups and qRTPCR was performed. Prox1 and other
YAP/TAZ target genes were
downregulated in the LECs of Vegfc+/−
pups. n=4 for each genotype. *P<0.05,
**P<0.01. Data are mean±s.e.m. Scale
bars: 200 µm in A-G″.
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report by Grimm et al., who elegantly showed that YAP is necessary
for VEGF-C-induced proliferation of LECs in zebrafish (Grimm
et al., 2019). The mechanisms and significance of this finding is
currently unknown.
Many important questions remain regarding the role of YAP and
TAZ in lymphatic vascular development. Multiple signaling
pathways including shear stress, Wnt/β-catenin signaling and
integrin/extracellular matrix signaling regulate YAP/TAZ activity
(Azzolin et al., 2014, 2012; Dupont et al., 2011; Frye et al., 2018;
Sabine et al., 2015; Zheng and Pan, 2019). These signaling
pathways also regulate lymphatic vascular development and valve
morphogenesis (Cha et al., 2016, 2018; Frye et al., 2018; Sabine
et al., 2012, 2015). It remains to be seen whether these signaling
pathways could activate YAP and TAZ in a functionally relevant
manner during lymphatic vascular development. In primary human
LECs, the transcription factor FOXC2 inhibits abnormal activation
of TAZ by oscillatory shear stress (Sabine et al., 2015).
Consequently, deletion of FOXC2 from the LVs of postnatal mice
results in the abnormal activation of TAZ leading to the loss of
quiescence, increased proliferation and apoptosis (Sabine et al.,
2015). Whether deletion of Yap and Taz could ameliorate valve
defects in mice lacking Foxc2 needs to be tested. Finally, XMUMP-1 is used pharmacologically to protect the heart against pressure
overload (Triastuti et al., 2019). It will be important to determine
whether XMU-MP-1 could be repurposed to treat lymphedema
when VEGFR3 signaling is compromised, as in the case of Milroy’s
disease.
MATERIALS AND METHODS
Antibodies

Primary antibodies for immunohistochemistry on mouse tissues were as
follows: rabbit anti-PROX1 (11-002, Angiobio; 1:500), goat anti-human
PROX1 (AF2727, R&D Systems; 1:500), sheep anti-mouse FOXC2
(AF6989, R&D Systems; 1:300), goat anti-mouse VEGRF3 (AF743,
R&D Systems; 1:300), rat anti-mouse CD31 (553,370, BD Pharmingen;
1:500), goat anti-human ANGPT2 (AF623, R&D Systems; 1:300), rabbit
anti-mouse LYVE-1 (11-034, Angiobio; 1:3000), rabbit anti-human/mouse
anti-YAP/TAZ (8418, Cell Signaling; 1:200), rabbit anti-human/mouse
TAZ (HPA007415, Sigma; 1:200), rabbit anti-human/mouse CTGF
(ab6992, Abcam; 1:200), rat anti-mouse endomucin (14-5851,
eBioscience; 1:3000), rabbit anti-ZO-1 (40-2200, Invitrogen; 1:100),
rabbit anti-human/mouse pHH3 (06-570, Millipore; 1:300) and goat antimouse GATA2 (AF2046, R&D Systems; 1:300).
Primary antibodies for immunocytochemistry: mouse anti-mouse/human
YAP (sc-101199, Santa Cruz; 1:100), mouse anti-mouse/human TAZ
(560235, BD Pharmingen; 1:100), goat anti-human PROX1 (AF2727, R&D
Systems; 1:500), rabbit anti-mouse/human ZO-1 (40-2200, Invitrogen;
1:100) and rabbit anti mouse/human β-catenin (9562, Cell Signaling;
1:200).
Secondary
antibodies
for
immunohistochemistry
and
immunocytochemistry were as follows: Cy3-conjugated donkey anti-rabbit
(711-165-152; 1:500), Cy3-conjugated donkey anti-sheep (711-165-147;
1:500), and Cy5-conjugated donkey anti-rat (712-175-150; 1:500) and Alexa
488-conjugated donkey anti-goat (705-545-147; 1:500) were purchased from
Jackson ImmunoResearch Laboratories. Alexa 488-conjugated goat antichicken (A-11039; 1:500) and Alexa 488-conjugated donkey anti-rat
(A-21208; 1:500) were purchased from Life Technologies.
Primary antibodies for western blotting were as follows: mouse antiβ-actin (A5441, Sigma; 1:100,000), goat anti-human PROX1 (AF2727, R&D
Systems; 1:1000), mouse anti-mouse/human YAP (sc-101199, Santa Cruz;
1:1000), mouse anti-mouse/human TAZ (560235, BD Pharmingen; 1:2000),
rabbit anti-human/mouse pYAP (4911, Cell Signaling; 1:500), rabbit anti
human/mouse Lats1/2 (3477, Cell Signaling; 1:500), rabbit anti-human/
mouse pLATS1/2 (8654, Cell Signaling; 1:500), rabbit anti human/mouse
pERK1/2 (4376, Cell Signaling; 1:1000), rabbit anti human/mouse ERK1/2
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TAZ are crucial for the PROX1 and VEGFR3 feedback loop during
the maturation stage of valve development.
YAP and TAZ are necessary for the proper functioning of
migratory tip cells during angiogenesis (Kim et al., 2017; Neto
et al., 2018; Sakabe et al., 2017; Wang et al., 2017). However,
lymphangiogenesis happens normally in Yap/TazLECKO embryos
until E16.5, after which their lymphatic vessels become
dramatically dilated. Considering the facts that CTGF expression
is enriched in valves, and that the onset of lymphatic vessel defects
in Yap/TazLECKO embryos coincides with the degeneration of LVs
and LVVs, we suggest that YAP and TAZ are playing a prominent
role in valvular endothelial cells. Thus, degeneration of LVs and
LVVs in Yap/TazLECKO embryos prevents lymphatic drainage,
resulting in the dilation of lymphatic vessels. Nevertheless,
lymphatic vessels of Prox1-heterozygous embryos that lack three
out of four Yap/Taz alleles develop abnormal cysts that are not seen
in Prox1+/− embryos that lack LVVs and LVs. Thus, YAP and TAZ
are likely also necessary in LECs. Additionally, deletion of Yap and
Taz in a Prox1-heterozygous background resulted in the abnormal
expression of endomucin in the LECs at E14.5. This phenotype is
partially reminiscent of embryos in which Prox1 was deleted after
the specification of LECs (Johnson et al., 2008). These results
suggest that YAP and TAZ play a modest role in promoting Prox1
expression in LECs.
In contrast to our findings, Cho et al. showed that YAP and TAZ
inhibit PROX1 expression in the developing lymphatic vessels (Cho
et al., 2019). The differences could be due to the distinct Cre lines
that were used. Although we used Lyve1-Cre, Cho et al. used Prox1CreERT2 (Bazigou et al., 2011). Although Cho et al. observed
severe edema in their mutant embryos, we did not observe edema in
most of our samples. The more severe phenotype observed by Cho
et al. could be due to more potent and/or rapid gene deletion by
Prox1-CreERT2. As mentioned above, we suspect that YAP and
TAZ play a primary role in maintaining the integrity of LVs and
LVVs. Degeneration of LVVs at an earlier stage in the Yap/
TazLECKO embryos generated by Cho et al. might have affected
lymphatic drainage earlier, which in turn would have prevented
lymphatic vessel maturation, resulting in sustained expression of
PROX1. Deleting Yap and Taz at various developmental time points
and in specific compartments of the lymphatic vasculature (LEC
progenitors, LECs, LVs, LVVs, tip cells and stalk cells) could test
these possibilities and provide better resolution of YAP and TAZ
activity.
There are also differences in in vitro data generated by Cho et al.
and us. Whereas we have determined that inhibition of YAP and
TAZ activity by VP or siRNA inhibits PROX1 expression, Cho
et al. draw the opposite conclusion from their results. It is possible
that these differences are due to differences in cell lines or culture
conditions that were used. Nevertheless, there are important points
of congruity between our findings and those of Cho et al.
Specifically, we also found that overactivation of YAP and TAZ,
via pharmacological inhibition of MST1/2 or RNAi-mediated
depletion of LATS1/2 reduces PROX1 expression in confluent
HLECs. These results – both loss and overactivation of YAP and
TAZ could result in the downregulation of PROX1 expression in the
lymphatic vasculature – suggest that a precise level of YAP and TAZ
activity regulates PROX1 expression.
Cell-density appears to function as a buffer that regulates YAP
and TAZ activity in response to VEGF-C. We found that VEGF-C
could reduce the phosphorylation of YAP and promote the
expression of YAP and TAZ target genes only in HLECs grown
under low-cell density. These later results are consistent with the
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(4695, Cell Signaling; 1:1000), mouse anti-human VEGFR3 (MAB3757,
Millipore; 1:1000) and rabbit anti GAPDH (PAB13195, Abnova; 1:1000).
HRP-conjugated secondary antibodies for western blotting were as
follows: goat anti-mouse IgG (A4416, Sigma; 1:5000), goat anti-rabbit IgG
(GtxRb-003-EHRPX, Immuno Reagent; 1:5000), donkey anti-goat IgG
(705-035-003, Jackson ImmunoResearch; 1:5000) and donkey anti-sheep
IgG (HAF016, R&D Systems; 1:5000).
Cells and chemicals

We used de-identified primary human lymphatic endothelial cells (HLECs)
for experiments. Dr Donwong Choi (Keck School of Medicine, University
of Southern California, USA) provided the HLECs (Choi et al., 2019,
2017a,b, 2016). HLECs were grown on gelatin-coated plates or glass slides
and were maintained in EBM2 media from Lonza. All experiments were
conducted using passage 5-6 cells. HLECs were treated as potential
biohazards and were handled according to institutional biosafety
regulations.
VEGF-C (9199-vc-025/CF, R&D Systems), verteporfin (SML0534,
Sigma Aldrich) and XMU-MP-1 (S8334, Selleck Chemicals) were diluted
in manufacturer’s recommended solvents.
Chromatin immunoprecipitation

ChIP assays were performed using the EZ-ChIP kit (MilliporeSigma)
according to the manufacturer’s instructions. Around 1.0×107 HLECs were
used per ChIP. Briefly, HLECs were grown on a culture dish at around 100%
confluence. Subsequently, HLECs were fixed in 1% formaldehyde for
10 min at room temperature and glycine at a final concentration of 0.125 M
was added for 5 min. Cells were washed with 20 ml of ice-cold PBS twice
(10 min each) and harvested. Cells were lysed and sonicated as previously
described (Cha et al., 2016, 2018).
Chromatin immunoprecipitation was performed using 0.2 μg of rabbit
anti-human YAP (ab52771, Abcam) or 1.0 μg of normal rabbit IgG
antibody (sc-2027, Santa Cruz Biotechnology). Following ChIP, PCR or qPCR was performed using primers flanking the predicted TEAD4-binding
site or a control site within the PROX1 promoter (5′-AGCCAGGGAATGAGTACAGG-3′ and 5′-AGGAAGCCTGTGCATTAACAC-3′).

Development (2020) 147, dev195453. doi:10.1242/dev.195453

were then washed with PBST and incubated with secondary antibodies for
2 h at room temperature, and then washed with PBST three times
(10 min each), mounted and visualized as previously described (Cha et al.,
2016, 2018).
Knockdown of YAP, TAZ, LATS1 and LATS2

HLECs were seeded at 40-50% confluence on plates. The following day,
cells were transfected with equal amounts of siControl (51-01-14-03,
Integrated
DNA
Technologies),
siYAP
(hs.Ri.YAP1.13.1,
hs.Ri.YAP1.13.3) and siTAZ (hs.Ri.TAZ.13.2, hs.Ri.TAZ.13.3) or
siLATS1 (hs.Ri.LATS1.13.1, hs.Ri.LATS1.13.3) and siLATS2
(hs.Ri.LATS2.13.2, hs.Ri.LATS2.13.3) using Lipofectamine RNAimax
(Thermo Fisher Scientific) according to the manufacturer’s instructions.
After 2-3 days cells were treated with VEGF-C and harvested with Trizol
(Invitrogen) or RIPA buffer for qRT-PCR or western blotting, respectively.
Mice

Prox1+/Cre (Srinivasan et al., 2010), Tg(Prox1-tdTomato) (Gong et al.,
2003), Lyve1-Cre (Pham et al., 2010), Vegfr3+/EGFP (Ichise et al., 2010),
Yapflox and Tazflox mice have been described previously (Xin et al., 2013,
2011). Vegfc+/CreERT2 mice were generated by Cyagen by inserting the
cDNA for CreERT2 immediately downstream of ATG at the Vegfc locus.
Mirimus generated the shVegfr3;rtTA3 mice according to their published
protocols (Premsrirut et al., 2011).
Prox1+/Cre mice were maintained in NMRI background. Other mice were
maintained in C57BL6 or C57BL6/NMRI mixed backgrounds. We used
both male and female mice for the experiments. All mice were housed and
handled according to the institutional IACUC protocols.
Regulatory element analysis

PROX1 regulatory elements were analyzed through ENCODE (ENCODE
Project Consortium, 2012). For targeted analysis, PROX1 regulatory
element sequences obtained from Ensembl were aligned using Clustal
Omega, and Homer was used for TEAD4 binding site identification (Heinz
et al., 2010; Madeira et al., 2019; Yates et al., 2020).
RNA-seq analysis

Immunohistochemistry on sections was carried out according to our
previously published protocols (Cha et al., 2016, 2018; Geng et al., 2016).
Briefly, freshly collected embryos were washed in 1× PBS and fixed in 4%
paraformaldehyde (PFA) overnight at 4°C. Subsequently, the embryos were
washed three times (10 min each) in ice-cold PBS, incubated in 15% sucrose
overnight at 4°C and then in 30% sucrose at 4°C until fully submerged in the
solution. Embryos were then cryo-embedded in OCT solution (Sakura,
Tokyo, Japan). Cryosections (12 μm) were prepared using a cryotome
(Thermo Fisher Scientific, HM525 NX) and immunohistochemistry was
performed using the indicated antibodies. E11.5 embryos were sectioned in
a transverse orientation and E12.0-E16.5 embryos were sectioned frontally.
Several consecutive sections were analyzed to determine the presence or
absence of LVVs and VVs.
Whole-mount immunohistochemistry using embryonic skin or guts was
performed according to our previous protocol (Cha et al., 2016, 2018).
Either whole embryos or isolated guts were washed in 1×PBS and fixed in
1% PFA for 1 h to overnight (depending on the antibody) at 4°C.
Subsequently, the dorsal skins were isolated, washed and samples were
immunostained using the iDISCO protocol (Renier et al., 2014). Samples
were visualized and analyzed as described previously (Cha et al., 2016,
2018). Fluorescent intensities were measured in a semi-quantitative manner
using ImageJ.
Immunostaining of cells

Cells were fixed in 1% PFA at room temperature for 30 min. Cells were
subsequently permeabilized with 0.3% Triton X-100 for 10 min at
room temperature, then washed with PBST (PBS+0.1% Triton-X100) and
blocked in 0.5% BSA PBST for 1 h at room temperature. Samples
were incubated with primary antibodies at 4°C overnight. Samples

Total RNA was purified from HLECs treated with VP for 2 h. RNA was
subjected to ribosomal RNA depletion followed by Truseq stranded total
RNA library preparation according to the manufacturer’s instruction
(Illumina). The resulting RNA-seq libraries were analyzed on the Illumina
HiSeq sequencing platform.
The obtained sequencing reads were mapped with the bowtie2 algorithm
using the RefSeq annotations (hg19 genome build) (Langmead and
Salzberg, 2012). We used the RNA-seq analysis work flow within the
Partek Genomics Suite (Partek Incorporated) for quantitation and statistical
analysis (ANOVA) of the transcriptome data. We identified those transcripts
that exhibited statistically significant differential expression in the VPtreated samples compared with the control samples. We rank ordered the two
lists based on the expression level and magnitude of change. Using these
rank-ordered lists, we performed gene ontology (GO) analysis for enriched
biological terms (Eden et al., 2009). The differentially expressed genes were
analyzed using the functional annotation platform of DAVID (Huang et al.,
2009a,b).
Scanning electron microscopy

Scanning electron microscopy was performed according to our previous
protocol (Geng et al., 2016; Geng and Srinivasan, 2018).
Statistical analysis

For biochemical analysis, n indicates the number of times the experiments
were independently performed and for histological analysis n indicates the
number of embryos analyzed per genotype. All experiments were performed
at least three times or more. Data were presented as mean±s.e.m. GraphPad
Prism 7 software was used to perform the statistical analysis. Data were
analyzed using the unpaired, two-tailed, Student’s t-test. P<0.05 was
considered significant.
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Immunohistochemistry of tissues

Western blot

Cells were harvested with RIPA lysis buffer and western blots were
performed using standard protocol. The density of bands was measured by
ImageJ and presented as mean±standard deviation (s.d.).
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